Whanin Pharmaceutical Company Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Whanin Pharmaceutical Company Limited with three other
companies in this sector in South Korea:
Myungmoon Pharmaceutical Company Limited
sales of 147.50 billion Korean Won [US$130.24 million]
of which 97%
was Manufacture and Sale of Pharmaceuticals),
JW Life Science Corp
(155.23 billion Korean Won [US$137.07 million]
Sam Chun Dang Pharm Co Ltd
(159.96 billion Korean Won [US$141.24 million]
of which 90%
was Finished Goods).
During the year ended December of 2018, sales at
Whanin Pharmaceutical Company Limited were 154.66 billion Korean Won (US$136.57 million).
increase of 4.5%
versus 2017, when the company's sales were 147.95 billion Korean Won.
Sales of Others saw an increase
that was more than double the company's growth rate: sales were up
31.0% in 2018, from
4.15 billion Korean Won to 5.44 billion Korean Won.
Whanin Pharmaceutical Company Limited also saw significant increases in sales in
Afentac (up 12.8% to 4.08 billion Korean Won)
Not all segments of Whanin Pharmaceutical Company Limited experienced an increase in sales in 2018:
sales of Atorvin fell 6.7% to 9.69 billion Korean Won.
Whanin Pharmaceutical Company Limited also experienced decreases in sales in
Urantac (down 1.8% to 8.94 billion Korean Won)
Proiban (down 3.1% to 5.17 billion Korean Won)